Caligan Partners
Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, RVMD, ABVX, PCVX, XENE, and represent 56.76% of Caligan Partners's stock portfolio.
- Added to shares of these 10 stocks: CGON (+$61M), RVMD (+$58M), SYRE (+$44M), LBRX (+$35M), SABS (+$31M), IRD (+$28M), MBX (+$25M), PCVX (+$21M), ADMA (+$18M), VOR (+$18M).
- Started 9 new stock positions in Xilio Therapeutics, CGON, SYRE, LBRX, SABS, MBX, AURA, SNSE, IRD.
- Reduced shares in these 6 stocks: MLYS (-$62M), INBX (-$37M), TNGX (-$28M), RAPT (-$22M), SPRB, ELDN.
- Sold out of its positions in ELDN, INBX, RAPT, SPRB.
- Caligan Partners was a net buyer of stock by $254M.
- Caligan Partners has $1.5B in assets under management (AUM), dropping by 23.71%.
- Central Index Key (CIK): 0001727492
Tip: Access up to 7 years of quarterly data
Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Caligan Partners
Caligan Partners holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 20.4 | $306M | 8.1M | 37.74 |
|
|
| Revolution Medicines (RVMD) | 12.2 | $183M | +46% | 1.9M | 97.25 |
|
| Abivax Sa Sponsored Ads (ABVX) | 10.8 | $163M | 1.5M | 111.35 |
|
|
| Vaxcyte (PCVX) | 8.0 | $120M | +20% | 2.1M | 58.11 |
|
| Xenon Pharmaceuticals (XENE) | 5.4 | $81M | +26% | 1.4M | 58.15 |
|
| Mineralys Therapeutics (MLYS) | 5.0 | $75M | -45% | 2.8M | 27.09 |
|
| Exelixis (EXEL) | 4.4 | $67M | 1.6M | 42.89 |
|
|
| Cg Oncology Call Option (CGON) | 4.1 | $61M | NEW | 900k | 67.68 |
|
| Tango Therapeutics (TNGX) | 3.4 | $50M | -35% | 2.4M | 20.92 |
|
| Tyra Biosciences (TYRA) | 3.3 | $49M | +35% | 1.3M | 38.30 |
|
| Adma Biologics (ADMA) | 3.0 | $46M | +67% | 5.1M | 9.01 |
|
| Spyre Therapeutics Com New (SYRE) | 2.9 | $44M | NEW | 878k | 50.44 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 2.3 | $35M | NEW | 1.4M | 24.08 |
|
| Vor Biopharma Com New (VOR) | 2.3 | $34M | +108% | 1.9M | 17.84 |
|
| Sab Biotherapeutics Com New (SABS) | 2.0 | $31M | NEW | 8.0M | 3.83 |
|
| Ocuphire Pharma (IRD) | 1.8 | $28M | NEW | 6.1M | 4.55 |
|
| Inventiva Sa Ads (IVA) | 1.8 | $28M | +148% | 5.0M | 5.55 |
|
| Mbx Biosciences (MBX) | 1.7 | $25M | NEW | 849k | 29.85 |
|
| Avalo Therapeutics Com New (AVTX) | 1.6 | $24M | +85% | 1.6M | 14.93 |
|
| Anika Therapeutics (ANIK) | 1.4 | $21M | 1.4M | 14.50 |
|
|
| Maze Therapeatics (MAZE) | 1.2 | $18M | +11% | 615k | 29.85 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.3 | $4.9M | 924k | 5.29 |
|
|
| Sensei Biotherapeutics Com New (SNSE) | 0.3 | $4.0M | NEW | 126k | 31.52 |
|
| Agios Pharmaceuticals Call Option (AGIO) | 0.2 | $3.0M | 90k | 33.83 |
|
|
| Aura Biosciences (AURA) | 0.1 | $1.5M | NEW | 230k | 6.69 |
|
| Xilio Therapeutics | 0.1 | $943k | NEW | 112k | 8.41 |
|
Past Filings by Caligan Partners
SEC 13F filings are viewable for Caligan Partners going back to 2022
- Caligan Partners 2026 Q1 filed May 15, 2026
- Caligan Partners 2025 Q4 filed Feb. 17, 2026
- Caligan Partners 2025 Q3 filed Nov. 14, 2025
- Caligan Partners 2025 Q2 filed Aug. 14, 2025
- Caligan Partners 2025 Q1 filed May 15, 2025
- Caligan Partners 2024 Q4 filed Feb. 14, 2025
- Caligan Partners 2024 Q3 filed Nov. 14, 2024
- Caligan Partners 2024 Q2 filed Aug. 14, 2024
- Caligan Partners 2024 Q1 filed May 13, 2024
- Caligan Partners 2023 Q4 filed Feb. 14, 2024
- Caligan Partners 2023 Q3 filed Nov. 14, 2023
- Caligan Partners 2023 Q2 filed Aug. 14, 2023
- Caligan Partners 2023 Q1 filed May 15, 2023
- Caligan Partners 2022 Q4 restated filed May 15, 2023
- Caligan Partners 2022 Q4 filed Feb. 15, 2023